Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study
Latest Information Update: 21 May 2025
At a glance
- Drugs Azercabtagene zapreleucel (Primary)
- Indications Multiple sclerosis; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Imugene
Most Recent Events
- 21 May 2025 New trial record